IL PIROXICAM FDDF PER VIA SUBLINGUALE NEL TRATTAMENTO DELL'ARTRITE REUMATOIDE

Translated title of the contribution: FDDF piroxicam for sublingual administration in the treatment of rheumatoid arthritis

C. Montecucco, R. Caporali, A. Ronchetti, S. Rossi, E. Comaschi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Open non-comparative study for the evaluation of the efficacy and tolerance of piroxicam FDDF for sublingual administration in the treatment of rheumatoid arthritis. Thirty patients (6 males and 24 females) suffering from rheumatoid arthritis in the active phase have been treated. All the patients had to fulfil the criteria for the rheumatoid arthritis classification proposed by the American Rheumatism Association (ARA). The efficacy of therapy has been evaluated, after 2, 4 and 6 week of treatment, through the changes in: the number of painful or tender joints on motion, the number of swollen joints, grip strength, ESR. Also day pain, night pain, duration of morning stiffness and functional index have been evaluated. As regards the functional index, activities as dressing, arising, eating, walking, taking care of hygiene, bending, standing and sitting have been considered. The study sample was composed by 30 patients, with a mean age of 59.73 years, suffering from rheumatoid arthritis from 4.76 years. As regards efficacy parameters, day pain, which is recorded on a 21 compartment visual analogue scale, was initially of 8.13 ( ± 3.73), and after 2 weeks of therapy decreased of about 1 point and after 4 weeks was of 6.57 (± 3.73). This improvement was already statistically significant at the first control (p = 0.01). At the first control also morning stiffness resulted improved in a statistically significant way (p <0.0001). As regards functional index a statistically significant improvement was observed in the disability of walking and of picking up objects after 2 weeks; after 4 weeks a significant improvement was observed in the disability of arising and of bending. These changes in functional ability probably depend upon the kind of joint involved and the duration of these lesions. Also the grip strength resulted statistically improved at the 2 control. As regards objective values, there was a statistically significant improvement in tender and swollen joints after only 2 weeks. As regards ESR, which is an index of disease activity, was initially of 40.73 (± 16.75) in mean; at the end of the 6th week it was of 34.72 (± 15.13): this reduction was statistically significant. No improvement was observed in night pain, normally the pain form which is more difficult to cure. As regards toleration, only 2 patients reported side effects: the first reported epigastralgia and the second oral burning. Both side-effects lasted 1 day and, according to the physician, their relation with the study drug is not sure. In conclusion, piroxicam FDDF demonstrated to be effective in the treatment of rheumatoid arthritis, both on symptoms and functional index, without systemic or local intolerance.

Original languageItalian
Pages (from-to)633-638
Number of pages6
JournalMinerva Medica
Volume85
Issue number12
Publication statusPublished - 1994

Fingerprint

Sublingual Administration
Piroxicam
Rheumatoid Arthritis
Pain
Joints
Hand Strength
Walking
Therapeutics
Aptitude
Bandages
Rheumatic Diseases
Hygiene
Visual Analog Scale
Eating
Physicians
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

IL PIROXICAM FDDF PER VIA SUBLINGUALE NEL TRATTAMENTO DELL'ARTRITE REUMATOIDE. / Montecucco, C.; Caporali, R.; Ronchetti, A.; Rossi, S.; Comaschi, E.

In: Minerva Medica, Vol. 85, No. 12, 1994, p. 633-638.

Research output: Contribution to journalArticle

@article{3b2b17b62e0b483599cd129741d46d91,
title = "IL PIROXICAM FDDF PER VIA SUBLINGUALE NEL TRATTAMENTO DELL'ARTRITE REUMATOIDE",
abstract = "Open non-comparative study for the evaluation of the efficacy and tolerance of piroxicam FDDF for sublingual administration in the treatment of rheumatoid arthritis. Thirty patients (6 males and 24 females) suffering from rheumatoid arthritis in the active phase have been treated. All the patients had to fulfil the criteria for the rheumatoid arthritis classification proposed by the American Rheumatism Association (ARA). The efficacy of therapy has been evaluated, after 2, 4 and 6 week of treatment, through the changes in: the number of painful or tender joints on motion, the number of swollen joints, grip strength, ESR. Also day pain, night pain, duration of morning stiffness and functional index have been evaluated. As regards the functional index, activities as dressing, arising, eating, walking, taking care of hygiene, bending, standing and sitting have been considered. The study sample was composed by 30 patients, with a mean age of 59.73 years, suffering from rheumatoid arthritis from 4.76 years. As regards efficacy parameters, day pain, which is recorded on a 21 compartment visual analogue scale, was initially of 8.13 ( ± 3.73), and after 2 weeks of therapy decreased of about 1 point and after 4 weeks was of 6.57 (± 3.73). This improvement was already statistically significant at the first control (p = 0.01). At the first control also morning stiffness resulted improved in a statistically significant way (p <0.0001). As regards functional index a statistically significant improvement was observed in the disability of walking and of picking up objects after 2 weeks; after 4 weeks a significant improvement was observed in the disability of arising and of bending. These changes in functional ability probably depend upon the kind of joint involved and the duration of these lesions. Also the grip strength resulted statistically improved at the 2 control. As regards objective values, there was a statistically significant improvement in tender and swollen joints after only 2 weeks. As regards ESR, which is an index of disease activity, was initially of 40.73 (± 16.75) in mean; at the end of the 6th week it was of 34.72 (± 15.13): this reduction was statistically significant. No improvement was observed in night pain, normally the pain form which is more difficult to cure. As regards toleration, only 2 patients reported side effects: the first reported epigastralgia and the second oral burning. Both side-effects lasted 1 day and, according to the physician, their relation with the study drug is not sure. In conclusion, piroxicam FDDF demonstrated to be effective in the treatment of rheumatoid arthritis, both on symptoms and functional index, without systemic or local intolerance.",
keywords = "piroxicam, rheumatoid arthritis",
author = "C. Montecucco and R. Caporali and A. Ronchetti and S. Rossi and E. Comaschi",
year = "1994",
language = "Italian",
volume = "85",
pages = "633--638",
journal = "Minerva Medicolegale e Archivio di Antropologia Criminale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "12",

}

TY - JOUR

T1 - IL PIROXICAM FDDF PER VIA SUBLINGUALE NEL TRATTAMENTO DELL'ARTRITE REUMATOIDE

AU - Montecucco, C.

AU - Caporali, R.

AU - Ronchetti, A.

AU - Rossi, S.

AU - Comaschi, E.

PY - 1994

Y1 - 1994

N2 - Open non-comparative study for the evaluation of the efficacy and tolerance of piroxicam FDDF for sublingual administration in the treatment of rheumatoid arthritis. Thirty patients (6 males and 24 females) suffering from rheumatoid arthritis in the active phase have been treated. All the patients had to fulfil the criteria for the rheumatoid arthritis classification proposed by the American Rheumatism Association (ARA). The efficacy of therapy has been evaluated, after 2, 4 and 6 week of treatment, through the changes in: the number of painful or tender joints on motion, the number of swollen joints, grip strength, ESR. Also day pain, night pain, duration of morning stiffness and functional index have been evaluated. As regards the functional index, activities as dressing, arising, eating, walking, taking care of hygiene, bending, standing and sitting have been considered. The study sample was composed by 30 patients, with a mean age of 59.73 years, suffering from rheumatoid arthritis from 4.76 years. As regards efficacy parameters, day pain, which is recorded on a 21 compartment visual analogue scale, was initially of 8.13 ( ± 3.73), and after 2 weeks of therapy decreased of about 1 point and after 4 weeks was of 6.57 (± 3.73). This improvement was already statistically significant at the first control (p = 0.01). At the first control also morning stiffness resulted improved in a statistically significant way (p <0.0001). As regards functional index a statistically significant improvement was observed in the disability of walking and of picking up objects after 2 weeks; after 4 weeks a significant improvement was observed in the disability of arising and of bending. These changes in functional ability probably depend upon the kind of joint involved and the duration of these lesions. Also the grip strength resulted statistically improved at the 2 control. As regards objective values, there was a statistically significant improvement in tender and swollen joints after only 2 weeks. As regards ESR, which is an index of disease activity, was initially of 40.73 (± 16.75) in mean; at the end of the 6th week it was of 34.72 (± 15.13): this reduction was statistically significant. No improvement was observed in night pain, normally the pain form which is more difficult to cure. As regards toleration, only 2 patients reported side effects: the first reported epigastralgia and the second oral burning. Both side-effects lasted 1 day and, according to the physician, their relation with the study drug is not sure. In conclusion, piroxicam FDDF demonstrated to be effective in the treatment of rheumatoid arthritis, both on symptoms and functional index, without systemic or local intolerance.

AB - Open non-comparative study for the evaluation of the efficacy and tolerance of piroxicam FDDF for sublingual administration in the treatment of rheumatoid arthritis. Thirty patients (6 males and 24 females) suffering from rheumatoid arthritis in the active phase have been treated. All the patients had to fulfil the criteria for the rheumatoid arthritis classification proposed by the American Rheumatism Association (ARA). The efficacy of therapy has been evaluated, after 2, 4 and 6 week of treatment, through the changes in: the number of painful or tender joints on motion, the number of swollen joints, grip strength, ESR. Also day pain, night pain, duration of morning stiffness and functional index have been evaluated. As regards the functional index, activities as dressing, arising, eating, walking, taking care of hygiene, bending, standing and sitting have been considered. The study sample was composed by 30 patients, with a mean age of 59.73 years, suffering from rheumatoid arthritis from 4.76 years. As regards efficacy parameters, day pain, which is recorded on a 21 compartment visual analogue scale, was initially of 8.13 ( ± 3.73), and after 2 weeks of therapy decreased of about 1 point and after 4 weeks was of 6.57 (± 3.73). This improvement was already statistically significant at the first control (p = 0.01). At the first control also morning stiffness resulted improved in a statistically significant way (p <0.0001). As regards functional index a statistically significant improvement was observed in the disability of walking and of picking up objects after 2 weeks; after 4 weeks a significant improvement was observed in the disability of arising and of bending. These changes in functional ability probably depend upon the kind of joint involved and the duration of these lesions. Also the grip strength resulted statistically improved at the 2 control. As regards objective values, there was a statistically significant improvement in tender and swollen joints after only 2 weeks. As regards ESR, which is an index of disease activity, was initially of 40.73 (± 16.75) in mean; at the end of the 6th week it was of 34.72 (± 15.13): this reduction was statistically significant. No improvement was observed in night pain, normally the pain form which is more difficult to cure. As regards toleration, only 2 patients reported side effects: the first reported epigastralgia and the second oral burning. Both side-effects lasted 1 day and, according to the physician, their relation with the study drug is not sure. In conclusion, piroxicam FDDF demonstrated to be effective in the treatment of rheumatoid arthritis, both on symptoms and functional index, without systemic or local intolerance.

KW - piroxicam

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0028577305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028577305&partnerID=8YFLogxK

M3 - Articolo

C2 - 7854556

AN - SCOPUS:0028577305

VL - 85

SP - 633

EP - 638

JO - Minerva Medicolegale e Archivio di Antropologia Criminale

JF - Minerva Medicolegale e Archivio di Antropologia Criminale

SN - 0026-4806

IS - 12

ER -